Update on SAR Studies Toward New COX-1 Selective Inhibitors

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Drug Discovery

Background:

• Cyclooxygenase-1 (COX-1) plays a role in carcinogenesis, neuroinflammation, cardiovascular diseases, and pain.
• Few selective COX-1 inhibitors exist, with mofezolac being a notable exception used clinically.
• Selective COX-1 inhibitors are often discovered serendipitously during the search for selective COX-2 inhibitors (COXIBs).

Purpose of the Study:

• To review newly synthesized selective COX-1 inhibitors from the past five years.
• To identify structural features that confer selectivity towards the COX-1 isoform.
• To provide a tool for designing novel selective COX-1 inhibitors for theranostic applications.

Main Methods:

• Literature review of recent studies on COX-1 inhibitors.
• Analysis of Structure-Activity Relationships (SAR) for COX-1 selectivity.
• Identification of key molecular determinants for COX-1 targeting.

Main Results:

• Several classes of novel selective COX-1 inhibitors have been identified.
• Specific molecular features influencing COX-1 selectivity have been elucidated for different chemical classes.
• The review synthesizes findings to guide future drug design.

Conclusions:

• Understanding the structural basis of COX-1 selectivity is essential for developing new therapeutics.
• This review offers insights for designing targeted COX-1 inhibitors for various diseases.
• The development of selective COX-1 inhibitors holds promise for theranostic approaches.